|Systematic (IUPAC) name|
|Trade names||Neupramir, Pramistar, Remen|
|(what is this?)|
Pramiracetam is a central nervous system stimulant and nootropic agent belonging to the racetam family of drugs. It is used in Eastern European countries and has the brand names Remen (Parke-Davis), Neupramir (Lusofarmaco), or Pramistar (Firma). It is not approved for any use by the US Food and Drug Administration or by the European Medicines Agency.
- Axel Kleemann, Jürgen Engel, Bernd Kutscher and Dietmar Reichert (2000). Pharmaceutical Substances (4th ed.). ISBN 978-1-58890-031-9.
- Vreese, De (1996). "Memory training and drug therapy act differently on memory and metamemory functioning: evidence from a pilot study". Gerontol Geriatr. 22: 9–22. doi:10.1016/0167-4943(96)86906-8. PMID 18653001.
Results showed that objective memory gains of the two groups receiving pramiracetam were significantly larger than that of the MT and CTR groups.
- Claus, JJ (April 1991). "Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam". Neurology 41 (4): 570–574. doi:10.1212/wnl.41.4.570. PMID 2011259.
Eight patients evidenced a best dose in the dose-finding phase, but in the subsequent replication phase only two again improved to a similar degree.
- McLean A Jr, Cardenas DD, Burgess D, Gamzu E (1991). "Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia". Brain Inj. 5 (4): 375–380. doi:10.3109/02699059109008110. PMID 1786500.